Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT04251169 |
| Title | Pembrolizumab + Paclitaxel in Hormone Receptor-positive (HR+)/Human Epidermal Growth Factor Receptor 2-negative (HER2-) Non-luminal (by PAM50) Advanced Breast Cancer After Cyclin-dependent Kinase 4/6 (CDK4/6) Inhibitors Progression (TATEN) |
| Acronym | TATEN |
| Recruitment | Terminated |
| Gender | both |
| Phase | Phase II |
| Variant Requirements | No |
| Sponsors | SOLTI Breast Cancer Research Group |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | ESP |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| ICO Hospitalet | Hospitalet de Llobregat | Barcelona | Spain | Details | ||
| Hospital Universitari Vall d'Hebrón | Barcelona | 08035 | Spain | Details | ||
| Hospital Clinic de Barcelona | Barcelona | Spain | Details | |||
| Hospital Universitario 12 de octubre | Madrid | Spain | Details | |||
| Hospital Quiron Salud Sagrado Corazon Sevilla | Sevilla | Spain | Details | |||
| Fundación Instituto Valenciano de Oncología | Valencia | 46009 | Spain | Details | ||
| Hospital Clínico Universitario de Valencia | Valencia | Spain | Details |